Sign inJoin waitlistJoin the waitlist

Joseph G. Jurcic

Director, Hematologic Malignancies Section · Columbia University Medical Center

Credentials: · · · ·

History

CUMC
Present

Memorial Sloan-Kettering Cancer Center
Barnes Jewish Hospital
Barnes Jewish Hospital
University of Pennslyvania School of Medicine
1988

Research

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
Science Translational Medicine · 2013 · 1,696 citations
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Blood · 2011 · 1,083 citations
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
New England Journal of Medicine · 2020 · 449 citations

DS
David Scheinberg
32 papers
PM
Peter Maslak
15 papers
Todd Rosenblat
12 papers
SL
Steven Larson
9 papers
JP
Jae Park
7 papers · 3 as a fellow
Mark Heaney
7 papers
Azra Raza
6 papers
Guillermo Garcia-Manero
6 papers
MT
Martin Tallman
6 papers
Mikkael Sekeres
6 papers
Nicole Lamanna
6 papers
PC
Philip Caron
6 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $902.3K · Columbia University Health Sciences
1997–2030
MSKCC Center for Molecular Imaging in Cancer
National Cancer Institute · P50
Project lead · $405.3K · Sloan-Kettering Inst Can Research
2008–2011

Clinical trials

DEC-C and Thioguanine for R/R AML
Principal investigator · Withdrawn · Phase 2
Columbia University
2024
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Principal investigator · Terminated · Phase 1
Joseph Jurcic
2022–2024
Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML
Principal investigator · Completed · Phase 1
Columbia University
2016–2020
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
Principal investigator · Completed · Phase 2
Chroma Therapeutics
2009–2011